The American College of Cardiology, together with the American Heart Association and the Heart Failure Society of America, have issued the second part of their guideline update on heart failure management. The first part was issued in May 2016.
The new update includes the following strong recommendations based on high-quality evidence:
- Natriuretic peptide biomarkers should be measured in patients presenting with dyspnea to help diagnose or exclude heart failure.
- B-type natriuretic peptide or N-terminal pro-B-type natriuretic peptide should be measured to determine prognosis or disease severity in chronic heart failure.
- Baseline natriuretic peptide biomarkers, cardiac troponin, or both should be measured upon hospital admission to determine prognosis in patients with acutely decompensated heart failure.